2024-07-08 14:36:33 ET
Summary
- Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026.
- The 4th pass of the safety review of the DMC was conducted, and it was noted that the phase 3 NATiV3 study should continue without modification.
- The global non-alcoholic steatohepatitis market is expected to reach $48.3 billion by the end of 2035.
- It could compete against other MASH companies with the use of lanifibranor by establishing several competitive advantages or by combining it with GLP-1 drugs.
Inventiva S.A. ( IVA ) is a well-established biotech, which is in the middle of running its phase 3 study using its drug lanifibranor for the treatment of patients with MASH, in the ongoing phase 3 NATiV3 clinical trial. I previously wrote about this biotech's prospects on using this drug to treat this patient population in a Seeking Alpha article entitled " Inventiva: Biotech To Consider Despite Short NASH Study Enrollment Pause. " I discussed the data it achieved to date and that the trial was allowed to continue with protocol amendments. Since then, there was a major development that was established, which was that there was a 4th Data Monitoring Committee [DMC] safety review pass....
Read the full article on Seeking Alpha
For further details see:
Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement